4 research outputs found
EASY (endoscopic approach to the symphysis): a new minimally invasive approach for the plate osteosynthesis of the symphysis and the anterior pelvic ring—a cadaver study and first clinical results
No full textA New Hierarchy of Research Evidence for Tumor Pathology: A Delphi Study to Define Levels of Evidence in Tumor Pathology
No full textThe hierarchy of evidence is a fundamental concept in evidence-based medicine, but existing models can be challenging to apply in laboratory-based health care disciplines, such as pathology, where the types of evidence and contexts are significantly different from interventional medicine. This project aimed to define a comprehensive and complementary framework of new levels of evidence for evaluating research in tumor pathology-introducing a novel Hierarchy of Research Evidence for Tumor Pathology collaboratively designed by pathologists with help from epidemiologists, public health professionals, oncologists, and scientists, specifically tailored for use by pathologists-and to aid in the production of the World Health Organization Classification of Tumors (WCT) evidence gap maps. To achieve this, we adopted a modified Delphi approach, encompassing iterative online surveys, expert oversight, and external peer review, to establish the criteria for evidence in tumor pathology, determine the optimal structure for the new hierarchy, and ascertain the levels of confidence for each type of evidence. Over a span of 4 months and 3 survey rounds, we collected 1104 survey responses, culminating in a 3-day hybrid meeting in 2023, where a new hierarchy was unanimously agreed upon. The hierarchy is organized into 5 research theme groupings closely aligned with the subheadings of the WCT, and it consists of 5 levels of evidence-level P1 representing evidence types that merit the greatest level of confidence and level P5 reflecting the greatest risk of bias. For the first time, an international collaboration of pathology experts, supported by the International Agency for Research on Cancer, has successfully united to establish a standardized approach for evaluating evidence in tumor pathology. We intend to implement this novel Hierarchy of Research Evidence for Tumor Pathology to map the available evidence, thereby enriching and informing the WCT effectively.The overall project, International Agency for Research on Cancer, and beneficiaries (German Heart Centre Munich, Maria Sklodowska-Curie National Research Institute of Oncology, and Instituto de Salud Carlos III) are funded by the European Commission (HORIZON grant no. 101057127). R.C. and F.C. are funded by UK Research and Innovation. S.H. has received research funding or honoraria from Roche, BMS, Merck, Sysmex, Thermo, Volition, Trillium, Medica, and Instand and is a founder of SFZ BioCoDE and CEBIO. P.H.T. has received honoraria from AstraZeneca.S
Mapping the Evidence for the World Health Organization (WHO) Classification of Tumours: a Living Evidence Gap Map by Tumour Type (WCT EVI MAP)
No full textThis project titled Mapping the Evidence for the World Health Organization (WHO) Classification of Tumours: a Living Evidence Gap Map by Tumour Type (WCT EVI MAP), lled by researchers of the WHO Classification of Tumours (WCT) programme at the International Agency for Research on Cancer (IARC), received a grant of €3.5 million from the European Commission (HORIZON-HLTH-2021-CARE-05 grant number 101057127) and has been developed under the umbrella of the International Collaboration for Cancer Classification and Research (IC3R).
This 4-year project, which is being undertaken in collaboration with six other international institutions, was launched on 1 July 2022.
The principal aim of the WCT EVI MAP project is to synthesize the existing evidence on cancer classification research to produce evidence gap maps (EGMs) for all known tumour types. These EGMs will make all the available evidence accessible, to inform the WHO Classification of Tumours, guide research efforts in all relevant fields of cancer research, and improve evidence-based practices within the broad community of scientists, clinicians, and decision-makers. This mapping exercise will emphasize existing evidence gaps and identify pockets of low-level evidence, as well as the overall quality level of the existing evidence. The final deliverable will be an open-access online tool that displays the results in an interactive way, enabling users to filter information tailored to their needs.
Improving cancer classification has a crucial impact on patient care, diagnosis, and treatment by informing decision-making processes with the best available evidence. By adapting the EGM methodology to the biomedical field, the WCT EVI MAP project is expected to promote the application of higher research standards in the field and to inspire researchers from other areas of public health to undertake similar projects
Moving Forward on Tumor Pathology Research Reporting: A Guide for Pathologists From the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group
No full textEvidence-based medicine (EBM) can be an unfamiliar territory for those working in tumor pathology research, and there is a great deal of uncertainty about how to undertake an EBM approach to planning and reporting histopathology-based studies. In this article, reviewed and endorsed by the Word Health Organization International Agency for Research on Cancer's International Collaboration for Cancer Classification and Research, we aim to help pathologists and researchers understand the basics of planning an evidence-based tumor pathology research study, as well as our recommendations on how to report the findings from these. We introduce some basic EBM concepts, a framework for research questions, and thoughts on study design and emphasize the concept of reporting standards. There are many study-specific reporting guidelines available, and we provide an overview of these. However, existing reporting guidelines perhaps do not always fit tumor pathology research papers, and hence, here, we collate the key reporting data set together into one generic checklist that we think will simplify the task for pathologists. The article aims to complement our recent hierarchy of evidence for tumor pathology and glossary of evidence (study) types in tumor pathology. Together, these articles should help any researcher get to grips with the basics of EBM for planning and publishing research in tumor pathology, as well as encourage an improved standard of the reports available to us all in the literature.The overall project, IARC, and beneficiaries (DHM, MSCI, ISCIII) are funded by the European Commission (HORIZON Grant No 101057127). R.C. and F.C. are funded by United Kingdom Research and Innovation (UKRI). R.C. is partly funded by mdxhealth inc. S.H. has received research funding or honoraria from Roche, BMS, Merck, Sysmex, Thermo, Volition, Trillium, Medica, and Instand and is founder of SFZ BioCoDE and CEBIO. P.H.T. has received honoraria from AstraZeneca.S
